Platinib is a targeted drug of several generations. What are its advantages?

Pralsetinib (Pralsetinib), as an innovative receptor tyrosine kinase RET inhibitor, is a third-generation targeted drug. It is designed to treat patients with cancers with specific genetic alterations, specifically those with metastatic rearrangement during transfection (RET) fusion-positive non-small cell lung cancer, and adult and pediatric patients 12 years and older with advanced or metastatic RET-mutant medullary thyroid carcinoma (MTC) or RET fusion-positive thyroid cancer. The launch of platinib provides these patient groups with more precise and efficient treatment options.

Platinib, as a third-generation targeted drug, has significant advantages over the previous two generationsRET inhibitors. First, it offers significant improvements in selectivity and specificity. Platinib can precisely target RET variations in tumor cells, including fusions and mutations, while showing lower affinity to other kinases. This high degree of selectivity not only improves the therapeutic effect, but also reduces damage to normal cells, thereby reducing the incidence of side effects.

Secondly, platinib has excellent performance in terms of efficacy. The results of multiple clinical trials show that Platinib has demonstrated excellent efficacy and significant clinical value in the treatment of RET fusion-positive non-small cell lung cancer and RET-mutant medullary thyroid cancer. The objective response rate (ORR) and disease control rate (DCR) of patients were significantly improved, and some patients even achieved complete response (CR). In addition, platinib also showed durable anti-tumor activity, helping to prolong progression-free survival (PFS) and overall survival (OS) of patients.

In addition, platinib was well tolerated, with a low incidence of adverse events, mostly mild to moderate. This means that patients can maintain a higher quality of life during treatment and reduce the physical and mental pain caused by treatment. The recommended dose of platinib is once a day, taken orally on an empty stomach, which not only facilitates patient medication, but also improves the compliance and convenience of treatment.

To sum up, platinib, as a third-generation targeted drug, shows significant advantages in selectivity, specificity, efficacy and tolerability. It provides new treatment options for cancer patients with RET gene mutations, helping to improve treatment success and survival rates.